The platelet inhibitor problem
Straub, P.W.
Schweizerische Medizinische Wochenschrift 111(14): 478-482
1981
ISSN/ISBN: 0036-7672 PMID: 7015489 Document Number: 180725
Some problems encountered in interpreting randomized clinical trials on the secondary prevention of myocardial infarction and transient cerebral ischemic attacks are discussed. With regard to acetylsalicylic acid, the dosage, and some general side effects such as those observed in transfusions, are considered.
Document emailed within 1 workday
Related Documents
Sills, T.; Heptinstall, S. 1986: Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour Thrombosis and Haemostasis 55(3): 305-308Macpherson, J.L.; Kemp, A.; Rogers, M.; Mallet, A.I.; Toia, R.F.; Spur, B.; Earl, J.W.; Chesterman, C.N.; Krilis, S.A. 1989: Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis Clinical and Experimental Immunology 77(3): 391-396
Sprengers, E.D.; Akkerman, J.W.; Jansen, B.G. 1986: Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood Thrombosis and Haemostasis 55(3): 325-329
Jackson, C.; Ball, J.; Peel, J.; Lawry, J.; Greaves, M.; Preston, F.E. 1989: DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect Thrombosis and Haemostasis 61(2): 266-269
García-Conde, J.; Merino, J.; Benet, I. 1978: Study of an inhibitor of platelet aggregation [prostacycline] derived from rat arterial wall Sangre 23(5): 526-534
Hara, H.; Tamao, Y.; Kikumoto, R.; Funahara, Y.; Hijikata, A.; Okamoto, S. 1980: Effect of a potent thrombin inhibitor, No. 407, on platelet function in vitro and in vivo Kobe Journal of Medical Sciences 26(1): 47-60
Weiss, D.J.; Evanson, O.A.; McClenahan, D.; Fagliari, J.J.; Dunnwiddie, C.T.; Wells, R.E. 1998: Effect of a competitive inhibitor of platelet aggregation on experimentally induced laminitis in ponies American Journal of Veterinary Research 59(7): 814-817
Matsueda, R.; Umeyama, H.; Puri, R.N.; Bradford, H.N.; Colman, R.W. 1994: Design and synthesis of a kininogen-based selective inhibitor of thrombin-induced platelet aggregation Peptide Research 7(1): 32-35
Akagi, M.; Nishioka, E.; Kanoh, R.; Tachibana, M.; Fukuishi, N. 1997: Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats Arzneimittel-Forschung 47(12): 1364-1369
Rosengarten, D.S.; McMichan, J.C.; Philipp, E. 1979: The effect of prophylactic proteinase inhibitor therapy on post-traumatic pulmonary insufficiency and platelet counts Advances in Experimental Medicine and Biology 120b: 349-360
De Clerck, F.; Vermylen, J.; Reneman, R. 1975: Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis. I. in vitro experiments Archives Internationales de Pharmacodynamie et de Therapie 216(2): 263-279
Kohga, S.; Kinjo, M.; Tanaka, K.; Ogawa, H.; Ishihara, M.; Tanaka, N. 1981: Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis Cancer Research 41(11 Part 1): 4710-4714
Rerkpattanapipat, P.; Kotler, M.N.; Yazdanfar, S. 1999: Images in cardiovascular medicine. Rapid dissolution of massive intracoronary thrombosis with platelet glycoprotein IIb/IIIa receptor inhibitor Circulation 99(22): 2965
Nizankowski, R.; Krzanowski, M.; Musiał, J.; Szczeklik, A. 1991: Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension Polski Tygodnik Lekarski 46(1-3): 18-21
Coudert, P.; Rubat, C.; Couquelet, J.; Tronche, P. 1990: Synthesis of 6-[(4-imidazol-1-yl)-phenyl]-4-phenyl 4,5-dihydro-2H-pyridazin-3-one: a potential blood platelet aggregation inhibitor Journal de Pharmacie de Belgique 45(3): 191-195
Barradas, M.A.; Stansby, G.; Hamilton, G.; Mikhailidis, D.P. 1994: Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients International Angiology: a Journal of the International Union of Angiology 13(3): 202-207
Yamada, S.; Yamada, R.; Nakamura, M. 1988: Study on mean platelet volume, platelet distribution width, platelet associated IgG in a family with hereditary thrombocytopenia Rinsho Byori. Japanese Journal of Clinical Pathology 36(6): 667-673
Dudek, D.; Bartuś, Sław.; Zmudka, K.; Kuta, M.; Legutko, J.; Wizimirski, M.; Pieniazek, P.; Przewłocki, T.; Gajos, G.; Bryniarski, L.; Dragan, J.; Pasowicz, Mław.; Zorkun, C.; Dubiel, J.S. 2002: Assessment of myocardial reperfusion in patients with acute myocardial infarction treated with combination of fibrinolysis and IIb/IIIa platelet inhibitor Przeglad Lekarski 59(1): 1-6
Suga, K.; Nishigauchi, K.; Kume, N.; Kishimoto, K.; Matsunaga, N.; Fujioka, K.; Zempo, N.; Kensuke, E. 1998: The effects of new platelet inhibitory drug E-5510 on platelet deposition on aortic bifurcation grafts: assessment by indium-111-oxime labeled platelet imaging Clinical Nuclear Medicine 23(6): 365-369
Kozai, T.; Shimokawa, H.; Fukumoto, Y.; Kobayashi, S.; Owada, M.K.; Kadokami, T.; Ito, A.; Kuwata, K.; Egashira, K.; Shiraishi, T.; Kanaide, H.; Takeshita, A. 1997: Tyrosine kinase inhibitor markedly suppresses the development of coronary lesions induced by long-term treatment with platelet-derived growth factor in pigs in vivo Journal of Cardiovascular Pharmacology 29(4): 536-545